乳腺癌根治术后放疗中组织等效填充物使用的研究进展  

Research progress on use of tissue equivalent filler in postmastectomy radiation therapy of breast cancer

作　　者：陈黎 钱建军[1] 田野[1] Chen Li;Qian Jianjun;Tian Ye(Department of Radiotherapy Oncology,the Second Affiliated Hospital of Soochow University,Institute of Radiotherapy Oncology,Soochow University,Suzhou Key Laboratory for Radiation Oncology,Suzhou 215004,China)

机构地区：[1]苏州大学附属第二医院放射治疗科,苏州大学放射肿瘤治疗学研究所,苏州市肿瘤放射治疗学重点实验室,苏州215004

出　　处：《中华放射肿瘤学杂志》2023年第2期184-188,共5页Chinese Journal of Radiation Oncology

基　　金：江苏省医学创新团队A类(CXDT-37)。

摘　　要：乳房切除术后放疗(PMRT)的使用已被证明为乳腺癌患者带来生存获益,但关于组织等效填充物(bolus)的使用仍存在争议。近年来大量研究表明PMRT中bolus的使用并不会显著提高患者的局部控制率,却因此明显增加了患者的急性皮肤不良反应,甚至可能导致更频繁和更长时间的治疗中断。现有的回顾性研究均表明对于接受乳房切除术和全身治疗的乳腺癌患者,如无皮肤侵犯,则建议在放疗期间不常规使用bolus,但还需要更高级别的临床研究进一步证实。Although the use of postmastectomy radiation therapy(PMRT)has been proven to bring survival benefit to breast cancer patients,the use of chest wall tissue equivalent filler(bolus)remains controversial.In recent years,a large number of studies have shown that the use of bolus in PMRT does not significantly improve the local control rate,while it can significantly increase the acute skin toxicity,and even leads to more frequent and longer treatment interruption.Existing retrospective studies have indicated that for breast cancer patients undergoing mastectomy and systemic therapy,if there is no skin invasion,it is recommended not to routinely use bolus during radiotherapy.However,higher-level clinical studies are needed for further confirmation.

关 键 词：乳腺肿瘤 乳房切除术后放射疗法 组织补偿物 皮肤不良反应 急性/晚期 局部控制率 

分 类 号：R737.9[医药卫生—肿瘤]